ETON - Company ID 0001710340
The table below shows Eton Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $37.59M | $24.27M | $22.46M | $18.93M | $17.28M | $10.32M |
| Cost of revenue | $12.18M | $9.53M | $14.60M | $7.00M | $7.42M | $4.02M |
| Gross profit | $25.41M | $14.73M | $7.86M | $11.92M | $9.86M | $6.30M |
| R&D | $993.00K | $1.88M | $1.11M | $3.71M | $1.16M | $505.00K |
Eton Pharmaceuticals, Inc. reported annual revenue of $79.95M for fiscal year 2025. That is up 104.9% from $39.01M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $959.00K (FY 2019) to $79.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $11.63M | $10.45M | $8.11M | $9.69M | $9.17M | $5.29M |
| Operating income | $12.79M | $2.41M | -$1.36M | -$1.48M | -$470.00K | $509.00K |
| Income tax | $140.00K | $20.00K | -$28.00K | $66.00K | $74.00K | -$126.00K |
| Net income | $11.58M | $1.55M | -$1.93M | -$2.58M | -$1.57M | $627.00K |
| EPS (diluted) | $0.35 | $0.05 | -$0.07 | -$0.10 | -$0.06 | $0.02 |